Add BrightSurf on Google Email

Antipsychotic drugs work differently than scientists believed

Researchers at Northwestern University discovered that antipsychotic drugs interact with a different neuron type than scientists originally believed, which could lead to better treatments for schizophrenia. The study's findings suggest that the effect of antipsychotics on dopamine receptors has little bearing on their efficacy in humans.

SourceNorthwestern University·JournalNature Neuroscience·TypeExperimental study·DateJul 18, 2023

Could drops replace eye injections for retina disease?

Researchers at Columbia University Irving Medical Center have discovered that an experimental eye drop treatment can reduce swelling and improve blood flow in the retina of mice with retinal vein occlusion, a common eye disease affecting up to 2% of people over age 40. The study found that the eye drops prevented neurons from deteriora...

SourceColumbia University Irving Medical Center·JournalFrontiers in Neuroscience·TypeExperimental study·DateJul 12, 2023

Fewer than half of new drugs add substantial therapeutic value over existing treatments

Fewer than half of new drugs approved for multiple indications in the US and Europe between 2011 and 2020 offered significant benefits over existing treatments. A study found that supplemental approvals were substantially less effective, suggesting a need to clearly communicate this information to patients and reflect it in drug prices.

SourceBMJ Group·JournalThe BMJ·TypeObservational study·DateJul 5, 2023

Treating childhood ADHD with stimulant meds not associated with increased substance use later in life, study finds

Researchers at the University of Pittsburgh School of Medicine found no evidence that prescription stimulant treatment in childhood increases the risk of substance use disorder (SUD) later in life. The study, published in JAMA Psychiatry, suggests that stimulants are an effective treatment for ADHD with few side effects.

SourceUniversity of Pittsburgh·JournalJAMA Psychiatry·DateJul 5, 2023

HKUMed in collaboration with the Hong Kong Sanatorium & Hospital, establishes the positive clinical impact of the Multidisciplinary Molecular Tumour Board among patients with advanced solid cancer in the era of Precision Cancer Medicine

The Multidisciplinary Molecular Tumour Board (MTB) has been shown to improve treatment response rates for patients with advanced solid cancer, with 64% of patients benefiting from the MTB-guided approach. The board provides a systematic precision oncology strategy for treatment selection, combining expertise in multiple disciplines.

SourceThe University of Hong Kong·JournalThe Lancet Regional Health - Western Pacific·TypeExperimental study·DateJul 4, 2023

The complex role of pyroptosis in lung cancer: a Chinese Medical Journal Pulmonary and Critical Care Medicine Review

Researchers explore pyroptosis as a potential therapeutic approach for lung cancer treatment. The review highlights the dual role of pyroptosis in tumor progression and negative impact on normal cells. It suggests balancing the contradictory effects of pyroptosis to optimize clinical applications.

SourceCactus Communications·JournalChinese Medical Journal - Pulmonary and Critical Care Medicine·TypeLiterature review·DateJun 28, 2023

TTUHSC-TTU research collaboration leads to possible drug targets for Leishmaniasis

The study found that drug-resistant Leishmania parasites have distinct protein production profiles compared to sensitive parasites, suggesting a global reprogramming of protein synthesis. This pre-emptive adaptation enables the parasite to quickly respond to the presence of the drug and survive when it is absent.

SourceTexas Tech University Health Sciences Center·JournalNature Communications·TypeExperimental study·DateJun 22, 2023

New Journal of Pharmaceutical Analysis articles showcase innovative approaches for diagnostics and drug screening and evaluation

Recent studies in the New Journal of Pharmaceutical Analysis feature novel diagnostic tools, RNA sequencing-based workflows, and mechanical property evaluations to enhance cancer and cardiovascular disease treatment outcomes. These innovations aim to improve the therapeutic effect of drugs and promote personalized medicine.

SourceCactus Communications·JournalJournal of Pharmaceutical Analysis·TypeExperimental study·DateJun 21, 2023

New research shows promising results for the development of a nonsurgical treatment for degenerative rotator cuff injury in the elderly

A novel study found that honokiol promotes healing of rotator cuff injury and may be an effective treatment for humans. The study suggests that SIRT3 activation plays a protective role in alleviating aging-induced fibrocartilage degeneration and promoting rotator cuff healing.

SourceElsevier·JournalAmerican Journal Of Pathology·TypeExperimental study·DateJun 20, 2023

Precious1GPT: multimodal transfer learning for aging clock development and target discovery

Researchers developed Precious1GPT, a multimodal transformer-based approach for aging clock development and feature importance analysis. The model utilizes methylation and transcriptomic data to predict biological age and identify disease-related genes, providing a pathway for therapeutic drug discovery.

SourceImpact Journals LLC·JournalAging-US·TypeRandomized controlled/clinical trial·DateJun 20, 2023

Ultrasound activation in cancer immunotherapy

Researchers have developed a sonodynamic cancer immunotherapy based on semiconducting polymer nanoparticles that can be activated by ultrasound, effectively treating orthotopic pancreatic cancer in mouse models. The treatment induces immunogenic cell death and kills cancer cells without causing excessive immune responses.

SourceWiley·JournalAngewandte Chemie International Edition·TypeExperimental study·DateJun 14, 2023

A patient with kidney cancer overcomes several metastases against all expectations. CNIO researchers discover why and pave the way for similar cases

A patient with kidney cancer overcame several metastases with temsirolimus, leading researchers to identify key mutations that make this treatment effective. The study found that patients with USP9X mutations have altered autophagy and respond better to temsirolimus.

SourceCentro Nacional de Investigaciones Oncológicas (CNIO)·JournalInternational Journal of Cancer·TypeExperimental study·DateJun 14, 2023

Blocking immune system 'messenger' may treat severe asthma

Researchers found that blocking histamine-releasing factor (HRF) and immunoglobulin E (IgE) interactions may provide relief for patients with severe asthma. The study, published in The Journal of Allergy and Clinical Immunology, suggests two potential therapies, including HRF-2CA and a therapeutic antibody called SPF7-1.

SourceLa Jolla Institute for Immunology·JournalJournal of Allergy and Clinical Immunology·TypeExperimental study·DateJun 12, 2023

University of Ottawa team leads promising new research on devastating brain disorder

A University of Ottawa team has discovered a vital role for the VGLUT3 transporter protein in modulating the development of Huntington's disease. The study shows that blocking glutamate release through this protein can lead to an amelioration of the disease progression, offering new hope for potential treatment approaches.

SourceUniversity of Ottawa·JournalNeurobiology of Disease·TypeExperimental study·DateJun 7, 2023

Two new studies identify promising pathways to treat chronic COVID-19

Two studies investigate long-term consequences of COVID-19, identifying potential drug targets for treating chronic disease. Researchers found novel pathways in the lungs and immune system that may lead to effective treatment options, including therapies targeting immune dysfunction and mucous cell differentiation.

SourceElsevier·JournalAmerican Journal Of Pathology·TypeObservational study·DateJun 6, 2023

Pumping the brakes on autoimmune disease

Researchers at Sanford Burnham Prebys have discovered a new treatment for autoimmune diseases using LY3361237, an antibody that activates BTLA to inhibit the immune system. The study provides insight into the molecular biology of the immune system and could lead to the development of more effective therapies.

SourceSanford Burnham Prebys·JournalStructure·DateJun 5, 2023

A supervised hospital walking program may reduce nursing facility admissions for older adults

A supervised hospital walking program has been shown to reduce nursing facility admissions for older adults by lowering the proportion of patients discharged to skilled nursing facilities from 13% to 8%. However, low participation rates and limited impact on length of stay or inpatient falls were noted.

SourceAmerican College of Physicians·JournalAnnals of Internal Medicine·TypeRandomized controlled/clinical trial·DateJun 5, 2023

Association of immunotherapy duration with overall survival in advanced non–small cell lung cancer – this study is being released to coincide with a poster presentation at the 2023 ASCO annual meeting

A study published in JAMA Oncology suggests that stopping immunotherapy after two years for patients with advanced non–small cell lung cancer who remain responsive may be a reasonable strategy, providing sustained clinical benefit. The findings provide reassurance for patients and their healthcare providers.

SourceJAMA Network·JournalJAMA Oncology·DateJun 4, 2023

NIH scientists find treatment for rare genetic skin disorder

Researchers at the National Human Genome Research Institute identified a potential treatment for disabling pansclerotic morphea, a severe inflammatory disease. They found that patients with the disorder have an overactive STAT4 protein and significantly improved symptoms with ruxolitinib, a JAK inhibitor.

SourceNIH/National Human Genome Research Institute·JournalNew England Journal of Medicine·TypeExperimental study·DateMay 31, 2023

UNDER EMBARGO: Mount Sinai researchers identify potential new treatment for those who act out their dreams while sleeping

Researchers have identified a novel model and therapy to mitigate the development of REM sleep behavior disorder, which affects over 3 million Americans. Dual orexin receptor antagonists have been shown to significantly reduce dream enactment behaviors, providing a promising new treatment option.